Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir

被引:127
作者
Ullrich, Sven [1 ]
Ekanayake, Kasuni B. [1 ]
Otting, Gottfried [1 ]
Nitsche, Christoph [1 ]
机构
[1] Australian Natl Univ, Res Sch Chem, Canberra, ACT 2601, Australia
基金
澳大利亚研究理事会;
关键词
SARS-CoV-2; Main protease; Variants; Nirmatrelvir; Inhibitors; CORONAVIRUS 3C-LIKE PROTEASE; DIMER INTERFACE; SARS; DIMERIZATION; CATALYSIS; MUTATIONS; VACCINES;
D O I
10.1016/j.bmcl.2022.128629
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The COVID-19 pandemic continues to be a public health threat. Multiple mutations in the spike protein of emerging variants of SARS-CoV-2 appear to impact on the effectiveness of available vaccines. Specific antiviral agents are keenly anticipated but their efficacy may also be compromised in emerging variants. One of the most attractive coronaviral drug targets is the main protease (M-pro). A promising M-pro inhibitor of clinical relevance is the peptidomimetic nirmatrelvir (PF-07321332). We expressed M-pro of six SARS-CoV-2 lineages (C.37 Lambda, B.1.1.318, B.1.2, B.1.351 Beta, B.1.1.529 Omicron, P.2 Zeta), each of which carries a strongly prevalent missense mutation (G15S, T21I, L89F, K90R, P132H, L205V). Enzyme kinetics reveal that these M-pro variants are catalytically competent to a similar degree as the wildtype. We show that nirmatrelvir has similar potency against the variants as the wildtype. Our in vitro data suggest that the efficacy of the specific M-pro inhibitor nirmatrelvir is not compromised in current COVID-19 variants.
引用
收藏
页数:4
相关论文
共 55 条
[1]  
Abdel Latif A, 2021, OUTBREAK INFO ORF1A
[2]  
Abdel Latif A., OUTBREAK INFO LINEAG
[3]  
Abdel Latif A., 2021, OUTBREAK INFO VARIAN
[4]   Proteases and protease inhibitors in infectious diseases [J].
Agbowuro, Ayodeji A. ;
Huston, Wilhelmina M. ;
Gamble, Allan B. ;
Tyndall, Joel D. A. .
MEDICINAL RESEARCH REVIEWS, 2018, 38 (04) :1295-1331
[5]   Dynamics prediction of emerging notable spike protein mutations in SARS-CoV-2 implies a need for updated vaccines [J].
Al-Zyoud, Walid ;
Haddad, Hazem .
BIOCHIMIE, 2021, 191 :91-103
[6]   Mutation of Asn28 Disrupts the Dimerization and Enzymatic Activity of SA RS 3CLpro [J].
Barrila, Jennifer ;
Gabelli, Sandra B. ;
Bacha, Usman ;
Amzel, L. Mario ;
Freire, Ernesto .
BIOCHEMISTRY, 2010, 49 (20) :4308-4317
[7]   COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants Comment [J].
Cevik, Muge ;
Grubaugh, Nathan D. ;
Iwasaki, Akiko ;
Openshaw, Peter .
CELL, 2021, 184 (20) :5077-5081
[8]   Mutation of Gly-11 on the dimer interface results in the complete crystallographic dimer dissociation of severe acute respiratory syndrome coronavirus 3C-like protease - Crystal structure with molecular dynamics simulations [J].
Chen, Shuai ;
Hu, Tiancen ;
Zhang, Jian ;
Chen, Jing ;
Chen, Kaixian ;
Ding, Jianping ;
Jiang, Hualiang ;
Shen, Xu .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (01) :554-564
[9]   Mutation of Glu-166 Blocks the Substrate-Induced Dimerization of SARS Coronavirus Main Protease [J].
Cheng, Shu-Chun ;
Chang, Gu-Gang ;
Chou, Chi-Yuan .
BIOPHYSICAL JOURNAL, 2010, 98 (07) :1327-1336
[10]   An interactive web-based dashboard to track COVID-19 in real time [J].
Dong, Ensheng ;
Du, Hongru ;
Gardner, Lauren .
LANCET INFECTIOUS DISEASES, 2020, 20 (05) :533-534